Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thiones | 9 | 2020 | 55 | 4.180 |
Why?
|
| Chromans | 9 | 2020 | 59 | 3.720 |
Why?
|
| Lung | 18 | 2018 | 382 | 3.080 |
Why?
|
| Antitubercular Agents | 8 | 2016 | 16 | 2.220 |
Why?
|
| Aerosols | 15 | 2018 | 43 | 2.040 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2020 | 37 | 1.710 |
Why?
|
| Administration, Inhalation | 18 | 2018 | 36 | 1.570 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2017 | 33 | 1.380 |
Why?
|
| Pharmaceutical Preparations | 5 | 2015 | 48 | 1.350 |
Why?
|
| Drug Delivery Systems | 11 | 2017 | 236 | 1.310 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 686 | 0.990 |
Why?
|
| Chemistry, Pharmaceutical | 8 | 2017 | 28 | 0.880 |
Why?
|
| Suppositories | 3 | 2020 | 7 | 0.860 |
Why?
|
| Cyclin D1 | 3 | 2018 | 38 | 0.850 |
Why?
|
| Guinea Pigs | 15 | 2016 | 73 | 0.830 |
Why?
|
| Animals | 32 | 2023 | 10684 | 0.820 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2019 | 131 | 0.760 |
Why?
|
| Administration, Oral | 8 | 2020 | 190 | 0.740 |
Why?
|
| Tuberculosis | 3 | 2012 | 25 | 0.710 |
Why?
|
| Capreomycin | 3 | 2012 | 3 | 0.710 |
Why?
|
| Powders | 8 | 2019 | 20 | 0.650 |
Why?
|
| Biological Availability | 6 | 2020 | 44 | 0.620 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2019 | 10 | 0.600 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2007 | 4 | 0.590 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2010 | 6 | 0.590 |
Why?
|
| Colistin | 1 | 2018 | 3 | 0.580 |
Why?
|
| Diestrus | 1 | 2018 | 2 | 0.580 |
Why?
|
| Tobramycin | 1 | 2018 | 13 | 0.580 |
Why?
|
| Estrus | 1 | 2018 | 23 | 0.580 |
Why?
|
| Particle Size | 8 | 2019 | 105 | 0.550 |
Why?
|
| Tuberculosis Vaccines | 3 | 2012 | 6 | 0.530 |
Why?
|
| Drug Carriers | 5 | 2013 | 119 | 0.520 |
Why?
|
| Ethionamide | 1 | 2016 | 1 | 0.520 |
Why?
|
| Technology, Pharmaceutical | 3 | 2013 | 9 | 0.510 |
Why?
|
| Nanoparticles | 4 | 2013 | 291 | 0.480 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2013 | 26 | 0.460 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2012 | 4 | 0.450 |
Why?
|
| Lung Diseases | 1 | 2015 | 43 | 0.430 |
Why?
|
| Administration, Intravaginal | 3 | 2018 | 12 | 0.430 |
Why?
|
| Mice | 8 | 2023 | 4802 | 0.420 |
Why?
|
| Azepines | 1 | 2013 | 2 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 536 | 0.420 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2013 | 12 | 0.410 |
Why?
|
| Nitroimidazoles | 2 | 2010 | 6 | 0.390 |
Why?
|
| Hypoglycemic Agents | 3 | 2003 | 110 | 0.390 |
Why?
|
| Cystic Fibrosis | 2 | 2003 | 34 | 0.380 |
Why?
|
| Nanomedicine | 1 | 2013 | 62 | 0.380 |
Why?
|
| Spleen | 5 | 2013 | 113 | 0.370 |
Why?
|
| Insulin | 3 | 2003 | 325 | 0.370 |
Why?
|
| Models, Animal | 3 | 2007 | 130 | 0.350 |
Why?
|
| Rifampin | 2 | 2009 | 7 | 0.330 |
Why?
|
| Half-Life | 3 | 2020 | 34 | 0.320 |
Why?
|
| Humans | 17 | 2023 | 28851 | 0.310 |
Why?
|
| Models, Biological | 3 | 2020 | 469 | 0.310 |
Why?
|
| Female | 11 | 2023 | 15624 | 0.300 |
Why?
|
| Area Under Curve | 2 | 2020 | 95 | 0.300 |
Why?
|
| Bacterial Vaccines | 2 | 2010 | 29 | 0.300 |
Why?
|
| Solubility | 2 | 2019 | 73 | 0.290 |
Why?
|
| X-Ray Diffraction | 2 | 2019 | 41 | 0.290 |
Why?
|
| Absorption | 4 | 2013 | 14 | 0.280 |
Why?
|
| Desiccation | 2 | 2019 | 5 | 0.280 |
Why?
|
| Dry Powder Inhalers | 2 | 2018 | 3 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 612 | 0.270 |
Why?
|
| Immunization | 1 | 2008 | 121 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 67 | 0.250 |
Why?
|
| Male | 10 | 2019 | 13921 | 0.250 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 607 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2003 | 124 | 0.230 |
Why?
|
| Microspheres | 5 | 2010 | 49 | 0.220 |
Why?
|
| Amino Acids | 2 | 2001 | 85 | 0.220 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 787 | 0.210 |
Why?
|
| Drug Compounding | 4 | 2018 | 32 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2012 | 1507 | 0.180 |
Why?
|
| Exosomes | 1 | 2023 | 96 | 0.180 |
Why?
|
| Limit of Detection | 2 | 2019 | 25 | 0.170 |
Why?
|
| Toxicity Tests | 1 | 2001 | 11 | 0.170 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 30 | 0.170 |
Why?
|
| Acetonitriles | 1 | 2019 | 2 | 0.150 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2019 | 3 | 0.150 |
Why?
|
| Freeze Drying | 1 | 2019 | 10 | 0.150 |
Why?
|
| Gastric Acid | 1 | 2019 | 19 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2018 | 65 | 0.140 |
Why?
|
| Tissue Distribution | 2 | 2020 | 137 | 0.140 |
Why?
|
| Polyglycolic Acid | 4 | 2010 | 38 | 0.140 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2017 | 36 | 0.140 |
Why?
|
| Lactic Acid | 4 | 2010 | 94 | 0.130 |
Why?
|
| Antigens, Bacterial | 2 | 2010 | 165 | 0.130 |
Why?
|
| Porosity | 1 | 2016 | 38 | 0.130 |
Why?
|
| Injections, Subcutaneous | 2 | 2013 | 60 | 0.110 |
Why?
|
| Time Factors | 2 | 2018 | 1613 | 0.110 |
Why?
|
| Bacterial Proteins | 2 | 2010 | 497 | 0.110 |
Why?
|
| Injections, Intramuscular | 2 | 2012 | 22 | 0.110 |
Why?
|
| Organ Size | 2 | 2006 | 88 | 0.110 |
Why?
|
| Calibration | 1 | 2013 | 29 | 0.100 |
Why?
|
| Mucociliary Clearance | 1 | 2013 | 3 | 0.100 |
Why?
|
| Transcytosis | 1 | 2013 | 4 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2012 | 2426 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 102 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 521 | 0.100 |
Why?
|
| Instillation, Drug | 3 | 2001 | 7 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 79 | 0.100 |
Why?
|
| Biological Transport | 1 | 2013 | 128 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 76 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 117 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2003 | 554 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 218 | 0.090 |
Why?
|
| Software | 1 | 2013 | 127 | 0.090 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2010 | 4 | 0.090 |
Why?
|
| Phenylthiourea | 1 | 2011 | 1 | 0.090 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 54 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 224 | 0.090 |
Why?
|
| Drug Stability | 3 | 2011 | 23 | 0.090 |
Why?
|
| Immunity, Cellular | 2 | 2010 | 23 | 0.090 |
Why?
|
| Respiratory Function Tests | 2 | 2001 | 27 | 0.090 |
Why?
|
| Diphtheria Toxin | 1 | 2010 | 6 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 737 | 0.080 |
Why?
|
| Hepatitis B Antigens | 1 | 2010 | 1 | 0.080 |
Why?
|
| Rats | 3 | 2003 | 1588 | 0.080 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Latent Tuberculosis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 82 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2013 | 916 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1025 | 0.080 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2009 | 2 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2009 | 68 | 0.070 |
Why?
|
| Tuberculin | 1 | 2008 | 1 | 0.070 |
Why?
|
| Mycobacterium smegmatis | 1 | 2008 | 3 | 0.070 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Leucine | 1 | 2008 | 20 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2008 | 14 | 0.070 |
Why?
|
| Humidity | 1 | 2008 | 7 | 0.070 |
Why?
|
| Microbial Viability | 1 | 2008 | 29 | 0.070 |
Why?
|
| Polyglactin 910 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1350 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2010 | 73 | 0.070 |
Why?
|
| Acyltransferases | 1 | 2007 | 24 | 0.070 |
Why?
|
| Drug Design | 1 | 2007 | 63 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 112 | 0.060 |
Why?
|
| Zidovudine | 2 | 1996 | 2 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 257 | 0.060 |
Why?
|
| Intubation, Intratracheal | 2 | 2001 | 27 | 0.060 |
Why?
|
| Swine | 2 | 2001 | 238 | 0.050 |
Why?
|
| Tropism | 1 | 2023 | 8 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 68 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2002 | 118 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 31 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2001 | 21 | 0.050 |
Why?
|
| Insufflation | 1 | 2001 | 1 | 0.040 |
Why?
|
| Pharmacokinetics | 1 | 2001 | 1 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 14 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 402 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 194 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 332 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 275 | 0.040 |
Why?
|
| Food, Formulated | 1 | 2017 | 11 | 0.030 |
Why?
|
| Emulsifying Agents | 1 | 2017 | 7 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 32 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 416 | 0.030 |
Why?
|
| Cell Line | 2 | 2009 | 700 | 0.030 |
Why?
|
| Delayed-Action Preparations | 2 | 2007 | 44 | 0.020 |
Why?
|
| Surface Properties | 2 | 2007 | 134 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1653 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 57 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 2 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 103 | 0.020 |
Why?
|
| Trehalose | 1 | 2009 | 3 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2009 | 32 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2009 | 36 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2009 | 37 | 0.020 |
Why?
|
| Monocytes | 1 | 2009 | 135 | 0.020 |
Why?
|
| Hybridomas | 1 | 2007 | 17 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 66 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2007 | 35 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 419 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 208 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2007 | 82 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 210 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 553 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2007 | 338 | 0.010 |
Why?
|
| Macrophages | 1 | 2007 | 305 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2001 | 310 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 1996 | 4 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 43 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1996 | 90 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 485 | 0.010 |
Why?
|
Garcia-Contreras's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(187)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_